Lomodine 2mg Capsules
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
LoModine 2mg Capsules
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Loperamide hydrochloride 2mg
For full list of excipients, see section 6.1
Contains lactose 100mg per capsule
3 PHARMACEUTICAL FORM
Size 4, green opaque cap and a mauve opaque body, hard gelatin capsule marked “LOMODINE 2” on the cap
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
For the symptomatic treatment of acute diarrhoea in adults and children aged 12 years and over.
For the symptomatic treatment of acute episodes of diarrhoea associated with Irritable Bowel Syndrome in adults and children aged 18 years and over following initial diagnosis by a doctor.
4.2 Posology and method of administration
The capsules should be taken with liquid.
Acute diarrhoea:
Adults and children over 12 years: two capsules (4mg) initially, followed by 1 capsule (2mg) after every loose stool. The usual dosage is 3 to 4 capsules (6mg-8mg) a day; the maximum daily dose should not exceed 6 capsules (12mg).
Symptomatic treatment of acute episodes of diarrhoea associated with Irritable Bowel Syndrome in adults and children aged 18 years and over:
Two capsules (4mg) to be taken initially, followed by 1 capsule (2mg) after every loose stool, or as previously advised by your doctor.
The maximum daily dose should not exceed 6 capsules (12mg).
If symptoms persist for more than 48 hours consult your doctor.
Use in elderly: No dose adjustment is required for the elderly.
Renal impairment
No dose adjustment is required for patients with renal impairment.
Hepatic impairment
Although no pharmacokinetic data are available in patients with hepatic impairment, Loperamide hydrochloride should be used with caution in such patients because of reduced first pass metabolism (see section 4.4 special warnings and special precautions for use).
Method of administration Oral use
4.3 Contraindications
LoModine 2mg capsules are contraindicated:
• in patients with known hypersensitivity to loperamide hydrochloride or to any of the excipients
• in children aged less than 12 years
• in patients with acute dysentery which is characterised by blood in stools and elevated body temperature.
• when ileus or constipation are present or when abdominal distension develops, especially in severely dehydrated children
• in patients with acute ulcerative colitis
• in patients with bacterial enterocolitis caused by invasive organisms including Salmonella, Shigella and Campylobacter
• in patients with pseudomembranous colitis associated with the use of broad spectrum antibiotics.
Loperamide should not be used when inhibition of peristalsis is to be avoided
due to the possible risk of significant sequelae including ileus, megacolon and
toxic megacolon. Loperamide must be discontinued promptly when
constipation, abdominal distension or ileus develop.
4.4 Special warnings and precautions for use
Treatment of diarrhoea with Loperamide is only symptomatic. Whenever an underlying etiology can be determined, specific treatment should be given when appropriate.
In patients with acute diarrhoea, especially in children, and in the frail and elderly fluid and electrolyte depletion may occur. In such cases administration of appropriate fluid and electrolyte replacement therapy is the most important measure. Loperamide should not be given to children under 12 years without medical prescription and supervision. Use of this product does not preclude the administration of appropriate fluid and electrolyte replacement therapy.
Since persistent diarrhoea can be an indicator of potentially more serious conditions, this medicine should not be used for prolonged periods until the underlying cause of the diarrhoea has been investigated.
In acute diarrhoea, if clinical improvement is not observed within 48 hours, the administration of Loperamide should be discontinued and patients should be advised to consult their doctor.
If patients are taking this medicine to control episodes of diarrhoea associated with Irritable Bowel Syndrome previously diagnosed by their doctor, and clinical improvement is not observed within 48 hours, the administration of Loperamide HCl should be discontinued and they should consult their doctor. Patients should also return to their doctor if the pattern of their symptoms changes or if the repeated episodes of diarrhoea continue for more than two weeks.
Patients with AIDS treated with Loperamide for diarrhoea should have therapy stopped at the earliest signs of abdominal distension. There have been isolated reports of toxic megacolon in AIDS patients with infectious colitis (viral or bacterial pathogens) treated with loperamide hydrochloride.
Although no pharmacokinetic data are available in patients with hepatic impairment, Loperamide should be used with caution in such patients because of first pass metabolism. Patients with hepatic dysfunction should be monitored closely for signs of central nervous system (CNS) toxicity.
Excipients
LoModine 2mg Capsules contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Special Warnings to be included in the leaflet:
Only take LoModine 2mg Capsules to treat acute episodes of diarrhoea associated with Irritable Bowel Syndrome if your doctor has previously diagnosed IBS.
If any of the following now apply, do not use the product without first consulting your doctor, even if you know you have IBS:
• If you are aged 40 or over and it is some time since your last IBS attack
• If you are aged 40 or over and your IBS symptoms are different this time
• If you have recently passed blood from the bowel
• If you suffer from severe constipation
• If you are feeling sick or vomiting
• If you have lost your appetite or lost weight
• If you have difficulty or pain passing urine
• If you have a fever
• If you have recently travelled abroad
Consult your doctor if you develop new symptoms, if your symptoms worsen, or your symptoms have not improved over two weeks.
4.5 Interaction with other medicinal products and other forms of interaction Effect of other medications on loperamide
In vitro studies have shown that loperamide is metabolised by cytochrome P450 3A4 and 2C8 enzymes and is a substrate for P-glycoprotein.
Opioid-like central nervous system effects have been reported in volunteer studies with concomitant administration of loperamide (16mg or 24mg single dose) with quinidine (600mg or 800mg). Quinidine may increase penetration of loperamide into the brain due to inhibition of central P-glycoprotein. The clinical significance of the pharmacokinetic interaction with P-glycoprotein inhibitors when loperamide is given at recommended dosages (2mg, up to 16mg maximum daily dose) is unknown.
Concomitant administration of loperamide 16mg and ritonavir, an inhibitor of both P-glycoprotein and CYP3A4, resulted in a two to three-fold increase in the AUC of loperamide but without evidence of enhanced central nervous system effect.
The concomitant administration of loperamide (4mg single dose) and
itraconazole, an inhibitor of CYP3A4 and P-glycoprotein, resulted in a 3 to 4fold increase in loperamide plasma concentrations. In the same study a CYP2C8 inhibitor, gemfibrozil, increased loperamide by approximately 2fold. The combination of itraconazole and gemfibrozil resulted in a 4-fold increase in peak plasma levels of loperamide and a 13-fold increase in total plasma exposure.
These increases were not associated with central nervous system (CNS) effects as measured by psychomotor tests (i.e., subjective drowsiness and the Digit Symbol Substitution Test).
The concomitant administration of loperamide (16mg single dose) and
ketoconazole, an inhibitor of CYP3A4 and P-glycoprotein, resulted in a 5-fold increase in loperamide plasma concentrations. This increase was not
associated with increased pharmacodynamic effects as measured by pupillometry.
Concomitant treatment with oral desmopressin resulted in a 3-fold increase of desmopressin plasma concentrations, presumably due to slower gastrointestinal motility.
It is expected that drugs with similar pharmacological properties may
potentiate loperamide’s effect and that drugs that accelerate gastrointestinal transit may decrease its effect.
4.6 Fertility, pregnancy and lactation
Although there are no indications that loperamide possesses teratogenic or embryotoxic properties, the anticipated therapeutic benefits should be weighed against potential hazards before loperamide is given during pregnancy, especially during the first trimester.
Small amounts of loperamide may appear in human breast milk. Therefore, loperamide is not recommended during breast feeding.
Women who are pregnant or breast-feeding should therefore be advised to consult their doctor for appropriate treatment.
4.7 Effects on ability to drive and use machines
Tiredness, loss of consciousness, depressed level of consciousness, dizziness or drowsiness may occur in the setting of diarrheal syndromes treated with Loperamide. Therefore, it is advisable to use caution when driving a car or operating machinery (See section 4.8, Undesirable effects).
4.8 Undesirable effects
The safety of loperamide HCl was evaluated in 3076 adults and children aged > 12 years who participated in 31 controlled and uncontrolled clinical trials of loperamide HCl used for the treatment of diarrhoea. Of these, 26 trials were in acute diarrhoea (N=2755) and 5 trials were in chronic diarrhoea (N=321).
The most commonly reported (i.e> 1% incidence) adverse drug reactions (ADRs) in clinical trials with loperamide HCl in acute diarrhoea were: constipation (2.7%), flatulence (1.7%), headache (1.2%) and nausea (1.1%). In clinical trials in chronic diarrhoea, the most commonly reported (i.e. >1% incidence) ADRs were: flatulence (2.8%), constipation (2.2%), nausea (1.2%) and dizziness (1.2%).
Table 1 displays ADRs that have been reported with the use of loperamide HCl from either clinical trial (in acute of chronic diarrhea or both) or post-marketing experience.
The frequency categories use the following convention: very common (>1/10);
common (>1/100 to <1/10); uncommon (>1/l,000 to <1/100); rare (>1/10,000 to <1/1.000); and very rare <1/10,000).
|
System organ class |
Indication | ||
|
Acute diarrhoea (N=2755) |
Chronic diarrhoea (N=321) |
Acute + chronic diarrhoea and postmarketing experience | |
|
Immune system disorders Hypersensitivity reaction3 Anaphylactic reaction (including anaphylactic shock)a , anaphylactoid reaction a |
Rare | ||
|
Nervous system disorders | |||
|
Headache |
Common |
Common |
Common |
|
Dizziness |
uncommon |
Uncommon |
Common |
|
Somnolence a |
Uncommon | ||
|
Loss of consciousness a, Stupor a Depressed level of consciousness a |
Rare | ||
|
Hypertonia a , co-ordination abnormality a | |||
|
Eye disorders Miosis a |
Rare | ||
|
Gastrointestinal disorders | |||
|
Constipation, nausea, flatulence |
Common |
Common |
Common |
|
Abdominal pain, abdominal discomfort, dry mouth |
Uncommon |
Uncommon |
Uncommon |
|
Abdominal pain upper, vomiting Dyspepsia Ileus a (including paralytic ileus) |
Uncommon |
Uncommon |
Uncommon Uncommon |
|
Megacolon a (including toxic megacolonb), glossodynia a,c |
Rare | ||
|
Abdominal distension |
Rare |
Rare | |
|
Skin and subcutaneous tissue disorders Rash |
Uncommon |
Uncommon | |
|
Skin and subcutaneous tissue disorders Bullous eruption a (including Stevens-Johnson syndrome), Toxic epidermal necrolysis and erythema multiforme), angioedema a , Urticaria a, Pruritus a |
Rare | ||
|
Renal and Urinary disorders Urinary retention a |
Rare | ||
|
General disorders and administration site conditions | |||
|
Fatigue a |
Rare |
a: Inclusion of this term is based on post-marketing reports for loperamide HCL. As the process for determining post marketing ADRs did not differentiate between chronic and acute indications or adults and children the frequency is estimated from all clinical trials with loperamide HCl combined, including trials in children :<12years (N=3683).
b: See section 4.4 Special Warnings and Special Precautions for use.
c: Reported for the orodispersible tablet only.
For clinical trial ADRs where no frequency is presented the term was not observed or considered an ADR for this indication.
Paediatric population
The safety of loperamide HCI was evaluated in 607 patients aged 10 days to 13 years who participated in 13 controlled and uncontrolled clinical trials of loperamide HCI used for the treatment of acute diarrhoea. In general, the ADR profile in this patient population was similar to that seen in clinical trials of loperamide HCl in adults and children aged 12 years and over.
A number of the adverse events reported during the clinical investigations and post-marketing experience with loperamide are frequent symptoms of the underlying diarrhoeal syndrome (abdominal pain/discomfort, nausea, vomiting, dry mouth, tiredness, drowsiness, dizziness, constipation, and flatulence). These symptoms are often difficult to distinguish from undesirable drug effects.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
4.9 Overdose
Symptoms
In case of overdose (including relative overdose due to hepatic dysfunction), CNS depression (stupor, coordination abnormality, somnolence, miosis, muscular hypertonia and respiratory depression), urinary retention and ileus may occur. Children may be more sensitive to CNS effects than adults.
Treatment
If symptoms of overdose occur, naloxone can be given as an antidote. Since the duration of action of loperamide is longer than that of naloxone (1 to 3 hours), repeated treatment with naloxone might be indicated. Therefore, the patient should be monitored closely for at least 48 hours in order to detect possible CNS depression.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Antipropulsives, A07D A03
Loperamide inhibits peristalsis and is used in the treatment of some diarrhoeas. Studies remain to be done to show the value of loperamide in acute infective diarrhoea. It should not be used to treat young children.
Loperamide is also used in ileostomy management to control the volume in discharge.
5.2 Pharmacokinetic properties
Loperamide is incompletely absorbed from the gastrointestinal tract. Its elimination half-life is reported to range from 7 to 15 hours. It is mainly excreted in the faeces.
Loperamide probably accumulates in the wall of the small intestine and is released extremely slowly.
5.3 Preclinical safety data
No data of relevance to the prescriber, which is additional to that included in other sections of the SPC.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Lactose monohydrate Maize starch Magnesium stearate Cap:
Quinoline yellow oxide (E104)
Indigo carmine (E132)
Titanium dioxide (E171)
Gelatin
Body:
Erythrosine (E127)
Indigo carmine (E132)
Black iron oxide (E172)
Titanium dioxide (E171)
Gelatin
6.2 Incompatibilities
None known
6.3 Shelf life
48 months
6.4 Special precautions for storage
Do not store above 25°C
6.5 Nature and contents of container
White, opaque PVC 250pm/hard temper aluminium foil 25 pm blister packs
Blister packaging: 4, 6, 8, 10, 16, 18 Not all pack sizes may be marketed
6.6 Special precautions for disposal
No specific instructions for use/handling
7 MARKETING AUTHORISATION HOLDER
Co-pharma Ltd Unit 4 Metro Centre Tolpits Lane Watford Hertfordshire WD18 9SS
8 MARKETING AUTHORISATION NUMBER(S)
PL 13606/0183
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
19/12/2011
19/06/2015